{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:42:57Z","timestamp":1791477777329,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein initially identified in prostate cancer (PCa) but also expressed in the neovasculature of various solid tumors. Recently, PSMA PET has emerged as a promising tool for detecting brain metastases (BMs) from non-prostatic cancers, offering diagnostic capabilities in addition to conventional imaging. This systematic review evaluates the role of PSMA-targeted radiopharmaceuticals in imaging BMs, highlighting their comparative diagnostic performance and exploring their potential for theranostic applications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review of the literature was conducted following PRISMA guidelines. Studies evaluating the diagnostic accuracy of PSMA PET imaging in identifying brain metastases (BMs) from non-prostatic solid tumors were included. Both full research articles and case reports were considered to capture the breadth of current evidence. The methodological quality of the included studies was assessed using the QUADAS-2 tool, and data were synthesized qualitatively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The review includes 23 studies reporting on 77 BMs from diverse primary malignancies, including lung, breast, salivary gland, thyroid, kidney, and melanoma. PSMA PET demonstrated high tumor-to-background ratios (TBR), enabling superior detection of BMs compared to conventional imaging modalities such as contrast-enhanced MRI and [18F]FDG PET. In post-radiotherapy cases, PSMA PET effectively differentiated radionecrosis from tumor recurrence. Moreover, PSMA PET demonstrated superior sensitivity in detecting thyroid metastases compared to traditional scintigraphy methods, highlighting its potential in cases where standard techniques yield inconclusive results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PSMA PET imaging shows significant promise in improving the diagnosis and management of BMs from non-prostatic cancers. While its theranostic applications remain underexplored, initial findings suggest promising avenues for integrating PSMA PET into personalized neuro-oncology care. Future studies should focus on standardizing imaging protocols, exploring PSMA PET utility in diverse tumor subtypes, and validating its role in clinical decision-making to maximize its impact on patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1553505","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:26:22Z","timestamp":1742189182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review"],"prefix":"10.3389","volume":"15","author":[{"given":"Sara","family":"Dall\u2019 Armellina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Aghakhanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore C.","family":"Fanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Aringhieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Faggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910620511","article-title":"Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids","volume":"62","author":"Troyer","year":"1995","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06490-z","article-title":"The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients","volume":"51","author":"Bauckneht","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B4","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res"},{"key":"B5","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B6","article-title":"Anatomic Pathology Division, Children\u2019s Hospital of Eastern Ontario, ON, Canada","author":"Segi","year":"2022"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.140608","article-title":"Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients","volume":"55","author":"Lapa","year":"2014","journal-title":"J Nucl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac131","article-title":"Investigational PET tracers in neuro-oncology-What\u2019s on the horizon? A report of the PET\/RANO group","volume":"24","author":"Galldiks","year":"2022","journal-title":"Neuro Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.3390\/cancers14164039","article-title":"PSMA radioligand uptake as a biomarker of neoangiogenesis in solid tumours: diagnostic or theragnostic factor","volume":"14","author":"Rizzo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1874471012666191017093721","article-title":"Potential of radiolabeled PSMA PET\/CT or PET\/MRI diagnostic procedures in gliomas\/glioblastomas","volume":"13","author":"Bertagna","year":"2020","journal-title":"Curr Radiopharm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/diagnostics14101002","article-title":"Prostate-specific membrane antigen positron emission tomography oncological applications beyond prostate cancer in comparison to other radiopharmaceuticals","volume":"14","author":"Miceli","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264850","article-title":"177Lu]Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: dosimetry results and critical statement","volume":"64","author":"Graef","year":"2023","journal-title":"J Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1220586","article-title":"PSMA-targeted therapy for non-prostate cancers","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/diagnostics13010158","article-title":"PSMA receptor-based PET-CT: the basics and current status in clinical and research applications","volume":"13","author":"Adnan","year":"2023","journal-title":"Diagnostics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001148","article-title":"PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer","volume":"41","author":"Taywade","year":"2016","journal-title":"Clin Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002103","article-title":"68Ga-labeled PSMA uptake in nonprostatic Malignancies: has the time come to remove \u201cPS\u201d From PSMA","volume":"43","author":"Malik","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002821","article-title":"18F-PSMA 1007 uptake in brain metastases from breast cancer","volume":"45","author":"Marafi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003336","article-title":"Recurrent brain metastasis of triple negative breast cancer with high uptake in 68Ga-PSMA-11 PET\/CT","volume":"46","author":"Arslan","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003813","article-title":"Rare brain metastasis in parotid adenoid cystic carcinoma detected on 68Ga-PSMA PET\/CT","volume":"46","author":"Datta Gupta","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004868","article-title":"Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET\/CT in the evaluation of adenoid cystic carcinoma-A prospective study","volume":"48","author":"Shamim","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/cancers16030667","article-title":"Head-to-head comparison of [18F]PSMA-1007 and [18F]FDG PET\/CT in patients with triple-negative breast cancer","volume":"16","author":"Andryszak","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13550-024-01148-9","article-title":"Potential application of [18F]AlF-PSMA-11 PET\/CT in radioiodine refractory thyroid carcinoma","volume":"14","author":"Van den Broeck","year":"2024","journal-title":"EJNMMI Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168443","article-title":"177 lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2825-5","article-title":"Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody","volume":"138","author":"Matsuda","year":"2018","journal-title":"J Neurooncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101616","DOI":"10.1016\/j.tranon.2023.101616","article-title":"The clinical application of 68Ga-PSMA PET\/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer","volume":"28","author":"Pei","year":"2023","journal-title":"Transl Oncol"},{"key":"B28","article-title":"A feasibility study of ga68-PSMA PET\/CT in differentiating brain metastases from radiation necrosis","author":"Lattuada","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004675","article-title":"Can PSMA-targeting PET\/CT be a valuable instrument to assess the presence of brain metastases in lung cancer patients?: A case report","volume":"48","author":"Dall\u2019Armellina","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.remn.2017.04.004","article-title":"A single brain metastasis seen on 68Ga-PSMA PET\/CT in recurrent breast cancer","volume":"37","author":"Medina-Ornelas","year":"2018","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.ebiom.2024.105068","article-title":"Potential of PSMA-targeting radioligand therapy for Malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging study","volume":"102","author":"Pruis","year":"2024","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"29","author":"Rowe","year":"2015","journal-title":"Ann Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04432-2","article-title":"The use of 68Ga-PET\/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma","volume":"46","author":"Raveenthiran","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003820","article-title":"68Ga-PSMA PET\/CT to distinguish brain metastasis of renal cell carcinoma from radiation necrosis after stereotactic radiosurgery","volume":"46","author":"Filizoglu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1271-2","article-title":"Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [18F]DCFPyL PET\/CT","volume":"21","author":"Yin","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.794759","article-title":"Head-to-head comparison of 68Ga-PSMA-11 and 131I in the follow-up of well-differentiated metastatic thyroid cancer: A new potential theragnostic agent","volume":"12","author":"Pitalua-Cortes","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003216","article-title":"Incidental detection of Malignant melanoma brain recurrence on 68Ga-prostate-specific membrane antigen PET\/CT","volume":"45","author":"Hod","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B38","article-title":"The role of 18F-PSMA-1007 PET-CT imaging in treatment management of Malignant brain tumors: pilot study from Azerbaijan","author":"Mehdi","year":"2023","journal-title":"J Nucl Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.htct.2024.04.102","article-title":"Comparison of PET\/CT images with 18F-FDG and 18F-PSMA-1007 in metastatic acral melanoma: a case report","volume":"46","author":"Mendanha","year":"2024","journal-title":"Hematology Transfusion Cell Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7150\/thno.38501","article-title":"68Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study","volume":"10","author":"van Boxtel","year":"2020","journal-title":"Theranostics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003142","article-title":"177Lu-\/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept","volume":"45","author":"Kumar","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17037","article-title":"Systematic review of the first 40 cases of177 lu-PSMA therapy in the treatment of non-prostatic cancer","volume":"44","author":"Golan","year":"2024","journal-title":"Anticancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2023.10.008","article-title":"An\u00e1lisis de coste de pruebas de nueva generaci\u00f3n en estadificaci\u00f3n de pacientes con c\u00e1ncer de pr\u00f3stata de alto riesgo","volume":"48","author":"Szczesniewski","year":"2024","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-08802-7","article-title":"Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis","volume":"32","author":"Ma","year":"2022","journal-title":"Eur Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1553505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:26:26Z","timestamp":1742189186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1553505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1553505"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1553505","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"article-number":"1553505"}}